Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model.
暂无分享,去创建一个
R. Schiffelers | G. Storm | M. Fens | Sylvia A Kuijpers | Sylvia A. Kuijpers | S. Kooijmans | M. Coimbra | Anil K Deshantri | A. Hoeppener
[1] K. Kang,et al. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells , 2015, Oncotarget.
[2] Lizhong Wang,et al. FOXP3-microRNA-146-NF-κB as oncotarget , 2015, Oncoscience.
[3] M. Junttila,et al. Translational value of mouse models in oncology drug development , 2015, Nature Medicine.
[4] Xiuping Liu,et al. FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. , 2015, Cancer research.
[5] D. Frank,et al. STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b , 2014, Cancers.
[6] A. Richardson,et al. STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes , 2014, Science Signaling.
[7] E. Elinav,et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.
[8] A. Palucka,et al. Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.
[9] J. Byrd,et al. Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies , 2012, Clinical Cancer Research.
[10] W. Hennink,et al. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[11] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[12] A. Borowsky. Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.
[13] Laura J. Esserman,et al. Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.
[14] P. Forgez,et al. Glucocorticoid receptor and breast cancer , 2011, Breast Cancer Research and Treatment.
[15] R. Lidereau,et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.
[16] Ana M. Aransay,et al. miRanalyzer: an update on the detection and analysis of microRNAs in high-throughput sequencing experiments , 2011, Nucleic Acids Res..
[17] K. Nicolay,et al. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[18] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[19] C. Gutiérrez,et al. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity. , 2011, Immunobiology.
[20] V. Fuster,et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. , 2010, Molecular pharmaceutics.
[21] Kazushi Inoue,et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer , 2009, Expert review of molecular diagnostics.
[22] R. Schiffelers,et al. Targeted delivery of anti-inflammatory agents to tumors. , 2009, Current pharmaceutical design.
[23] R. Schiffelers,et al. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. , 2008, International journal of pharmaceutics.
[24] S. Schokrpur,et al. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.
[25] D. DeFranco,et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. , 2008, Cancer research.
[26] R. Schiffelers,et al. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[27] R. Schiffelers,et al. Utility of Targeted Glucocorticoids in Cancer Therapy , 2008 .
[28] R. Cardiff,et al. Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. , 2006, Cancer research.
[29] K. Livak,et al. Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.
[30] R. Schiffelers,et al. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. , 2005, Neoplasia.
[31] C. Khanna,et al. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. , 2004, European journal of cancer.
[32] M. Wauben,et al. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. , 2003, Arthritis and rheumatism.
[33] S. Hundertmark,et al. Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. , 1997, The Journal of endocrinology.
[34] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Langer,et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.
[36] S. Fleischer,et al. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots , 1970, Lipids.
[37] Chundong Yu,et al. Associations of miR-146a and miR-146b expression and breast cancer in very young women. , 2015, Cancer biomarkers : section A of Disease markers.